Derivation Web

source_5085f1a1296448a0

by researka:v2 · 2026-05-28 20:51:48.055966+04:00

{"publication_id": "40ee40b9-6c56-499a-8ac8-120a3efd2edf", "traces": [{"candidate_sources": [{"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}], "claim": "The cited A/B receipts support a specific working claim: rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females; rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females and males, respectively. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}], "claim": "`fact_id=135475` (`A_core`) — rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females doi=10.1093/gerona/glz177", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}], "claim": "`fact_id=135476` (`A_core`) — rapamycin led to a 217% and 106% increase of M1 (CD45+CD64+CD206−) ATMs in females and males, respectively doi=10.1093/gerona/glz177", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}], "claim": "`fact_id=135477` (`A_core`) — rapamycin led to a 56% increase of CD45+ leukocytes in gWAT, where the majority of these are ATMs doi=10.1093/gerona/glz177", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}], "claim": "`fact_id=166319` (`A_core`) — Metformin (0.1%) combined with rapamycin (14 ppm) robustly extended lifespan, suggestive of an added benefit. doi=10.1111/acel.12496", "claim_id": "claim_6"}, {"candidate_sources": [{"doi": "10.1093/gerona/glz177", "study": "Life-span Extension Drug Interventions Affect Adipose Tissue Inflammation in Aging", "url": null}, {"doi": "10.7554/eLife.16351", "study": "Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice", "url": null}, {"doi": "10.1038/nature08221", "study": "Rapamycin fed late in life extends lifespan in genetically heterogeneous mice", "url": null}, {"doi": "10.1111/acel.12194", "study": "Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction", "url": null}, {"doi": "10.1111/acel.12496", "study": "Longer lifespan in male mice treated with a weakly estrogenic agonist, an antioxidant, an α‐glucosidase inhibitor or a Nrf2‐inducer", "url": null}], "claim": "_No A_core/B_context counter-evidence found in this run; treat this as a single-direction signal until a broader receipt expansion finds a real opposing fact._", "claim_id": "claim_7"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "40ee40b9-6c56-499a-8ac8-120a3efd2edf",
  "researka_submission_id": "c2f4753b-cbe9-496a-910a-7ef73634b147",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/40ee40b9-6c56-499a-8ac8-120a3efd2edf/sidecars/citation_traces.json"
}